← FDA DRUG APPROVALS

FDA ANDA · ANDA205872

CISATRACURIUM BESYLATE PRESERVATIVE FREE

Sponsor: ACCORD HLTHCARE

APPLICATION
ANDA205872
TYPE
ANDA
ORIGINAL APPROVAL
2017-06-16
LATEST ACTION
2025-04-25
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

CISATRACURIUM BESYLATE PRESERVATIVE FREEDiscontinued
CISATRACURIUM BESYLATE EQ 10MG BASE/ML · INJECTABLE · INJECTION
CISATRACURIUM BESYLATE PRESERVATIVE FREEDiscontinued
CISATRACURIUM BESYLATE EQ 2MG BASE/ML · INJECTABLE · INJECTION

Approval history

2025-04-25Labeling · Supplement 5 · standardAP
2017-06-16UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →